{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:38:07Z","timestamp":1770280687105,"version":"3.49.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.atherosclerosis.2021.09.001","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T02:40:14Z","timestamp":1631155214000},"page":"16-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation"],"prefix":"10.1016","volume":"335","author":[{"given":"Peter A.","family":"Senior","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus\u2013related all\u2010cause and cardiovascular mortality in a national cohort of adults","volume":"8","author":"Raghavan","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group","volume":"329","author":"Group","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib7","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Group","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib9","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib10","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib11","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib14","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA\u00a0: J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib16","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib18","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib20","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib25","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib27","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/dia.2018.0384","article-title":"State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018","volume":"21","author":"Foster","year":"2019","journal-title":"Diabetes Technol. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib30","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1111\/dom.13842","article-title":"Glycaemic variability: the under\u2010recognized therapeutic target in type 1 diabetes care","volume":"21","author":"Wilmot","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib31","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/dc16-1769","article-title":"Toward defining the threshold between low and high glucose variability in diabetes","volume":"40","author":"Monnier","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib32","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome--a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib33","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00125-015-3857-4","article-title":"Life expectancy of type 1 diabetic patients during 1997\u20132010: a national Australian registry-based cohort study","volume":"59","author":"Huo","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib34","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.2337\/db10-0862","article-title":"Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes","volume":"59","author":"Secrest","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2213-8587(14)70248-7","article-title":"Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis","volume":"3","author":"Huxley","year":"2015","journal-title":"Lancet Diabet. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib36","doi-asserted-by":"crossref","first-page":"e2032","DOI":"10.1210\/clinem\/dgaa015","article-title":"Risk factors for cardiovascular disease (CVD) in adults with type 1 diabetes: findings from prospective real-life T1D exchange registry","volume":"105","author":"Shah","year":"2020","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib37","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/1753-0407.12622","article-title":"Metabolic memory: evolving concepts","volume":"10","author":"Misra","year":"2018","journal-title":"J. Diabetes"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib39","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2337\/dc15-1990","article-title":"Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT\/EDIC study 30-year follow-up","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib40","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2337\/dc15-2283","article-title":"Nine-year effects of 3.7 Years of intensive glycemic control on cardiovascular outcomes","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib42","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","article-title":"Follow-up of blood-pressure lowering and glucose control in type 2 diabetes","volume":"371","author":"Zoungas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib43","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1806802","article-title":"Intensive glucose control in patients with type 2 diabetes \u2014 15-year follow-up","volume":"380","author":"Reaven","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib44","doi-asserted-by":"crossref","DOI":"10.2337\/dc20-3104","article-title":"Associations of microvascular complications with the risk of cardiovascular disease in type 1 diabetes","author":"Gubitosi-Klug","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib45","series-title":"Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO\/IDF ConsultatIon","year":"2006"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib46","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2337\/diacare.20.7.1183","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus","volume":"20","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2337\/dc10-1206","article-title":"Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes","volume":"34","author":"Colagiuri","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib48","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archopht.1984.01040030398010","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy: II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years","volume":"102","author":"Klein","year":"1984","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib49","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/BF00403913","article-title":"Familial factors determine the development of diabetic nephropathy in patients with IDDM","volume":"39","author":"Quinn","year":"1996","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"10.1016\/j.atherosclerosis.2021.09.001_bib50","first-page":"32","article-title":"The relationship between microalbuminuria in first generation diabetic and non-diabetic subjects and microalbuminuria and hypertension in the second generation (a population based study)","volume":"12","author":"Vestbo","year":"1997","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib51","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2337\/diacare.28.8.2019","article-title":"Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study)","volume":"28","author":"Thorn","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib52","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2337\/dc08-2022","article-title":"Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes","volume":"32","author":"Thorn","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJM198407123110204","article-title":"Predicting diabetic nephropathy in insulin-dependent patients","volume":"311","author":"Mogensen","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00285287","article-title":"Albuminuria reflects widespread vascular damage","volume":"32","author":"Deckert","year":"1989","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib55","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2012.11.031","article-title":"US renal data system 2012 annual data report","volume":"61","author":"Collins","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib56","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/TP.0b013e3181ff4f61","article-title":"Cardiovascular assessment of diabetic end-stage renal disease patients before renal transplantation","volume":"91","author":"Welsh","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib57","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2337\/diacare.28.4.866","article-title":"Coronary artery disease is common in nonuremic, asymptomatic type 1 diabetic islet transplant candidates","volume":"28","author":"Senior","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib58","series-title":"Transplantation, bioengineering, and regeneration of the endocrine pancreas","first-page":"349","author":"Gruessner","year":"2020"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib59","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00125-015-3853-8","article-title":"Long-term cardiovascular outcomes in type 1 diabetic patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation","volume":"59","author":"Lindahl","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib60","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/diacare.25.5.906","article-title":"Impact of simultaneous pancreas and kidney transplantation on progression of coronary atherosclerosis in patients with end-stage renal failure due to type 1 diabetes","volume":"25","author":"Jukema","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib61","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/TP.0b013e318247a782","article-title":"Long-term (5 Years) efficacy and safety of pancreas transplantation alone in type 1 diabetic patients","volume":"93","author":"Boggi","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib62","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.2337\/dc14-0061","article-title":"Amelioration of cardiac morphology and function in type 1 diabetic patients with sustained success of pancreas transplant alone","volume":"37","author":"Occhipinti","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib63","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2337\/dc15-1988","article-title":"Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia","volume":"39","author":"Hering","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib64","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM200007273430401","article-title":"Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen","volume":"343","author":"Shapiro","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib65","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2337\/diabetes.54.7.2060","article-title":"Five-year follow-up after clinical islet transplantation","volume":"54","author":"Ryan","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib66","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2337\/dc12-0063","article-title":"Improvement in outcomes of clinical islet transplantation: 1999-2010","volume":"35","author":"Barton","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib67","doi-asserted-by":"crossref","first-page":"dc141686","DOI":"10.2337\/dc14-1686","article-title":"Glycemic control in simultaneous islet-kidney versus pancreas-kidney transplantation in type 1 diabetes: a prospective 13-year follow-up","volume":"38","author":"Lehmann","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib68","series-title":"CITR 10th Annual Report","year":"2017"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14570","article-title":"Effects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes","volume":"38","author":"Reid","year":"2021","journal-title":"Diabet. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib70","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/01.TP.0000061788.32639.D9","article-title":"Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation1","volume":"75","author":"Fiorina","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib71","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2337\/diacare.26.4.1129","article-title":"Long-term beneficial effect of islet transplantation on diabetic macro-\/microangiopathy in type 1 diabetic kidney-transplanted patients","volume":"26","author":"Fiorina","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib72","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2337\/diacare.28.6.1303","article-title":"Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients","volume":"28","author":"Fiorina","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib73","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2337\/dc12-0679","article-title":"Reduction in carotid intima-media thickness after pancreatic islet transplantation in patients with type 1 diabetes","volume":"36","author":"Danielson","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib74","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2337\/db14-0059","article-title":"Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia","volume":"63","author":"Cryer","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib75","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib76","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib77","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International consensus on use of continuous glucose monitoring","volume":"40","author":"Danne","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib78","doi-asserted-by":"crossref","first-page":"dci190028","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib79","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1001\/archinte.164.19.2090","article-title":"Postprandial glucose regulation and diabetic complications","volume":"164","author":"Ceriello","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib80","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.295.14.1681","article-title":"Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes","volume":"295","author":"Monnier","year":"2006","journal-title":"JAMA\u00a0: J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib81","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-002032","article-title":"Glycemic variability and cardiovascular disease in patients with type 2 diabetes","volume":"9","author":"Martinez","year":"2021","journal-title":"BMJ Open Diabet. Res. Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib82","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2016.19975","article-title":"Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial","volume":"317","author":"Beck","year":"2017","journal-title":"JAMA\u00a0: J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib83","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/M16-2855","article-title":"Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial","volume":"167","author":"Beck","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib84","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s001250051279","article-title":"Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells","volume":"42","author":"Jones","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib85","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/CIRCRESAHA.120.316653","article-title":"Transient intermittent hyperglycemia accelerates atherosclerosis by promoting myelopoiesis","volume":"127","author":"Flynn","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib86","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.cmet.2013.04.001","article-title":"Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis","volume":"17","author":"Nagareddy","year":"2013","journal-title":"Cell Metabol."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib87","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s10020-018-0060-3","article-title":"The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review","volume":"24","author":"Fishman","year":"2018","journal-title":"Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib88","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/dia.2017.0388","article-title":"Beyond HbA1c: comparing glycemic variability and glycemic indices in predicting hypoglycemia in type 1 and type 2 diabetes","volume":"20","author":"Chandran","year":"2018","journal-title":"Diabetes Technol. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib89","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2337\/dc09-2082","article-title":"Hypoglycemia, diabetes, and cardiovascular events","volume":"33","author":"Desouza","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib90","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.2337\/db17-0306","article-title":"Severe hypoglycemia-induced fatal cardiac arrhythmias are augmented by diabetes and attenuated by recurrent hypoglycemia","volume":"66","author":"Reno","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib91","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMra1215228","article-title":"Mechanisms of hypoglycemia-associated autonomic failure in diabetes","volume":"369","author":"Longo","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib92","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","article-title":"Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management","volume":"7","author":"Group","year":"2019","journal-title":"Lancet Diabet. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib93","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.2337\/dc14-0405","article-title":"Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden","volume":"37","author":"Lung","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib94","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2337\/dc14-0920","article-title":"Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study","volume":"38","author":"Khunti","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib95","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2337\/dc15-2418","article-title":"A population-based study of all-cause mortality and cardiovascular disease in association with prior history of hypoglycemia among patients with type 1 diabetes","volume":"39","author":"Lu","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib96","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/dme.12810","article-title":"Association between hypoglycaemia and impaired hypoglycaemia awareness and mortality in people with Type 1 diabetes mellitus","volume":"33","author":"Sejling","year":"2016","journal-title":"Diabet. Med."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib97","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/dom.14172","article-title":"Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes","volume":"22","author":"Ali","year":"2020","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.atherosclerosis.2021.09.001_bib98","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11892-020-01339-3","article-title":"Assessment of risks and benefits of beta cell replacement versus automated insulin delivery systems for type 1 diabetes","volume":"20","author":"Senior","year":"2020","journal-title":"Curr. Diabetes Rep."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021013174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021013174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:47:46Z","timestamp":1758156466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915021013174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":98,"alternative-id":["S0021915021013174"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.09.001","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}